LYELL IMMUNOPHARMA IN

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

07 Nov 2024 16:05:03 By Nasdaq GlobeNewswire

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

05 Nov 2024 09:30:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

31 Oct 2024 16:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

24 Oct 2024 16:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

04 Oct 2024 09:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

24 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces Participation in September Investor Conferences

28 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

07 Aug 2024 16:05:01 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

26 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

03 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

07 May 2024 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

06 May 2024 08:00:01 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

05 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

28 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces Participation in March Investor Conferences

26 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

09 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

07 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing

31 Oct 2023 09:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

27 Sep 2023 09:00:00 By Nasdaq GlobeNewswire